If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  FDA To Review AIDS Drug Application May 29, 1996 -- The U. S. Food and Drug Administration's Antiviral Drug Advisory Committee meeting will be meeting on Friday, June 7, to discuss a new drug application submitted by Boehringer Ingelheim Pharmaceuticals to the U.S. Food and Drug Administration for Viramune (nevirapine), a non-nucleoside reverse transcriptase inhibitor (NNRTI). Boehringer Ingelheim Pharmaceuticals is the first company with a drug in this new class to seek accelerated approval from the FDA. VIRAMUNE® is proposed for use in combination therapy to treat HIV infection. Boehringer Ingelheim Pharmaceuticals and its sister company, Roxane Laboratories, are collaborating in the marketing of VIRAMUNE®. This collaboration capitalizes on Boehringer Ingelheim Pharmaceuticals' extensive clinical development capabilities and Roxane Laboratories' unique experience in HIV disease. The committee meeting will begin at 8:30 a.m. in the Maryland Ballroom at the Quality Inn, Silver Spring, Maryland. The Quality Inn is located at 8727 Colesville Road at the intersection of Georgia Avenue and can be contacted at 301-589-5200. For further information about VIRAMUNE and/or the upcoming AVDAC meeting, please contact either Brian Hujdich (202-944-5142) or Ryan Peal (202-944-5163; rpeal@hillandknowlton.com).
|
